Menlo Therapeutics Inc. (42) | Uncategorized (12)

Recent Contracts

Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart (Filed With SEC on March 17, 2022)
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 17, 2022)
Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda (Filed With SEC on March 17, 2022)
Evaluation and Option Agreement, dated as of April 30, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc (Filed With SEC on November 10, 2021)
Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc (Filed With SEC on August 12, 2021)
Offer Letter, dated as of April 7, 2021, by and between Mutya Harsch and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)
Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc (Filed With SEC on May 6, 2021)
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)
Offer Letter, dated as of March 25, 2020, by and between Menlo Therapeutics Inc. and David Domzalski (Filed With SEC on May 11, 2020)
Offer Letter, dated as of March 20, 2020, by and between Menlo Therapeutics Inc. and Andrew Saik (Filed With SEC on May 11, 2020)
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 3, 2020)
Form of CSR Agreement (Filed With SEC on November 12, 2019)